LMR Partners’s BridgeBio Pharma BBIO Stock Holding History

LMR Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,400	Closed	-$2.78M	–	1467
2025 Q4	$2.78M	Hold	36,400	–	–	0.01%	728
2025 Q3	$1.89M	Hold	36,400	–	–	0.01%	752
2025 Q2	$1.57M	Hold	36,400	–	–	0.01%	701
2025 Q1	$1.26M	Sell	36,400 -107,300	-75%	-$3.62M	0.01%	740
2024 Q4	$3.94M	Buy	143,700 +43,700	+44%	+$1.13M	0.03%	446
2024 Q3	$2.55M	Buy	100,000 +80,000	+400%	+$2.1M	0.02%	538
2024 Q2	$507K	Buy	+20,000	New	+$547K	﹤0.01%	767
2024 Q1	–	Sell	-25,000	Closed	-$1.01M	–	1159
2023 Q4	$1.01M	Buy	+25,000	New	+$751K	0.01%	580
2023 Q3	–	Sell	-5,400	Closed	-$92.9K	–	940
2023 Q2	$92.9K	Buy	+5,400	New	+$81.3K	﹤0.01%	629

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LMR Partners's BBIO Position: Q2 2026 in Review

LMR Partners opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 54,130 shares worth $4.03M. The stake represents 0.02% of the portfolio and ranks #722 among its holdings. This is a return to the name: LMR Partners previously reported a position in BBIO as recently as Q3 2025.

LMR Partners first reported a position in BBIO in Q2 2023 and has held it in 7 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

LMR Partners held 54,130 shares of BridgeBio Pharma worth $4.03M as of Q2 2026.
BridgeBio Pharma was a new LMR Partners position in Q2 2026.
BridgeBio Pharma made up 0.02% of LMR Partners's portfolio in Q2 2026, its #722 holding.
LMR Partners first reported a position in BridgeBio Pharma in Q2 2023 and has held it in 7 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.